.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.

Christoph H. Borchers

Montreal / CA

Jewish General Hospital

Vortrag

Mo., 21.10.
Poster presentation
P-I-0107
SysQuan: a novel strategy for the absolute quantitation of human proteins
New Technology: MS-based Proteomics

Weitere Beteiligungen

Mo., 21.10.
Poster presentation
P-I-0107
SysQuan: a novel strategy for the absolute quantitation of human proteins
New Technology: MS-based Proteomics
Mo., 21.10.
15:52 – 16:04 10 Min. 2 Min.
Oral presentation
OP-14
Identification of novel diagnostic protein biomarkers in human plasma for breast cancer by targeted protein assay
Clinical Proteomics
Di., 22.10.
Poster presentation
P-II-0559
LiP-MS guided drug discovery using the cancer driver Ras as a model system
Structural Proteomics
Di., 22.10.
Poster presentation
P-II-0631
Optimizing capivasertib response prediction in cancer: unveiling resistance mechanisms through precision proteomics
Clinical Proteomics
Di., 22.10.
Poster presentation
P-II-0632
Quantification of Her2 expression in Her2-low tumors by targeted mass spectrometry
Clinical Proteomics
Di., 22.10.
Poster presentation
P-II-0621
Harmonization of quantitative proteomics data collected across the international cancer proteogenome consortium
Clinical Proteomics
Di., 22.10.
Poster presentation
P-II-0625
Targeted quantitative proteomics of anticoagulated patients
Clinical Proteomics
Mi., 23.10.
Poster presentation
P-III-0810
A pipeline for designing proteogeno-typic peptide standards to quantify variants: the potential of neutrophil elastase in proteogenomics
Data Integration: With Bioinformatics to Biological Knowledge